JP2018510617A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510617A5
JP2018510617A5 JP2017540250A JP2017540250A JP2018510617A5 JP 2018510617 A5 JP2018510617 A5 JP 2018510617A5 JP 2017540250 A JP2017540250 A JP 2017540250A JP 2017540250 A JP2017540250 A JP 2017540250A JP 2018510617 A5 JP2018510617 A5 JP 2018510617A5
Authority
JP
Japan
Prior art keywords
seq
antibody
heavy chain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510617A (ja
JP7101927B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/050416 external-priority patent/WO2016120811A1/en
Publication of JP2018510617A publication Critical patent/JP2018510617A/ja
Publication of JP2018510617A5 publication Critical patent/JP2018510617A5/ja
Application granted granted Critical
Publication of JP7101927B2 publication Critical patent/JP7101927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540250A 2015-01-28 2016-01-28 抗トランスサイレチン抗体 Active JP7101927B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562109004P 2015-01-28 2015-01-28
US62/109,004 2015-01-28
US201562266555P 2015-12-11 2015-12-11
US62/266,555 2015-12-11
PCT/IB2016/050416 WO2016120811A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (3)

Publication Number Publication Date
JP2018510617A JP2018510617A (ja) 2018-04-19
JP2018510617A5 true JP2018510617A5 (enExample) 2019-03-07
JP7101927B2 JP7101927B2 (ja) 2022-07-19

Family

ID=55300737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540250A Active JP7101927B2 (ja) 2015-01-28 2016-01-28 抗トランスサイレチン抗体

Country Status (25)

Country Link
US (1) US20160257737A1 (enExample)
EP (1) EP3250593B1 (enExample)
JP (1) JP7101927B2 (enExample)
KR (1) KR102649788B1 (enExample)
CN (1) CN107406500B (enExample)
AU (1) AU2016210889C1 (enExample)
CA (1) CA2974993A1 (enExample)
CO (1) CO2017008482A2 (enExample)
CU (1) CU20170098A7 (enExample)
DK (1) DK3250593T3 (enExample)
EA (1) EA036014B1 (enExample)
ES (1) ES2925716T3 (enExample)
HR (1) HRP20220918T1 (enExample)
HU (1) HUE059592T2 (enExample)
MX (1) MX389911B (enExample)
MY (1) MY193701A (enExample)
PE (1) PE20180218A1 (enExample)
PL (1) PL3250593T3 (enExample)
PT (1) PT3250593T (enExample)
RS (1) RS63513B1 (enExample)
SA (1) SA517381981B1 (enExample)
SG (2) SG11201706126WA (enExample)
SI (1) SI3250593T1 (enExample)
TW (2) TWI711631B (enExample)
WO (1) WO2016120811A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
MA50619A (fr) 2017-10-04 2020-08-12 Amgen Inc Fusions d'immunoglobulines de transthyrétine
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
MX2020003041A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
PH12020550694A1 (en) * 2017-11-29 2021-04-12 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin
US12006357B2 (en) 2018-06-26 2024-06-11 Mor Research Applications Ltd. Transthyretin antibodies and uses thereof
CN111018976B (zh) * 2018-10-10 2022-04-01 东莞市朋志生物科技有限公司 一种抗人心肌肌钙蛋白i的重组抗体
WO2020094883A1 (en) * 2018-11-09 2020-05-14 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
TW202110882A (zh) * 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
SG11202112762TA (en) * 2019-07-08 2021-12-30 Amgen Inc Multispecific transthyretin immunoglobulin fusions
CN116249717A (zh) 2020-06-24 2023-06-09 普罗塞纳生物科学有限公司 识别分拣蛋白的抗体
CN116635024A (zh) * 2020-10-14 2023-08-22 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
CN116601295A (zh) * 2020-12-03 2023-08-15 江苏恒瑞医药股份有限公司 一种抗tslp抗体药物组合物及其用途
US20240052050A1 (en) * 2020-12-16 2024-02-15 Merus N.V. Multispecific antibodies for the treatment of cancer
JP2024535756A (ja) 2021-09-07 2024-10-02 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド バイオマーカー組成物およびその使用方法
CN116804186B (zh) * 2023-07-05 2023-12-22 中国兽医药品监察所 一种抗鸡传染性贫血病毒单克隆抗体杂交瘤细胞株、单克隆抗体、试剂或试剂盒及其应用
TW202525341A (zh) 2023-12-15 2025-07-01 丹麥商諾佛 儂迪克股份有限公司 穩定的液體調配物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE371231T1 (de) 1999-02-05 2007-09-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zur wiederauffindung von texturbildern
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ, スーパーヒト化抗体
WO2003057838A2 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
SG182160A1 (en) 2007-03-02 2012-07-30 Boehringer Ingelheim Pharma Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2015010118A2 (en) * 2013-07-19 2015-01-22 The University Of Texas Transthyretin amyloid-selective and polyreactive catabodies

Similar Documents

Publication Publication Date Title
JP2018510617A5 (enExample)
JP2018506277A5 (enExample)
JP2018509889A5 (enExample)
JP7663977B2 (ja) 抗pd―l1抗体およびその用途
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
JP2017535257A5 (enExample)
JP2016507523A5 (enExample)
JP2018531219A6 (ja) Pd−l1抗体
JP2018531219A (ja) Pd−l1抗体
JP2012525829A5 (enExample)
JP2011509245A5 (enExample)
JP2020536532A5 (enExample)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2010526028A5 (enExample)
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2016512551A5 (enExample)
JP2019528082A (ja) アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
CN104136042A (zh) 使用抗假单胞菌Psl和PcrV结合分子的联合治疗
JP2019532617A5 (enExample)
CN109689684B (zh) 具有低免疫原性的抗体及其用途
US12173081B2 (en) CD19/CD38 multispecific antibodies
CN114502595B (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
JP2020513759A5 (enExample)
AU2019349662A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
CN106164094A (zh) 双特异性抗原结合多肽